BZBD sprinted to the main board of the Shanghai Stock Exchange and is expected to raise 1 billion yuan

 Jiangsu BZBD has submitted a prospectus to be listed on the main board of the Shanghai Stock Exchange. BZBD plans to raise 1 billion yuan, of which 920 million yuan will be used for the Liaoning production base construction project and 80 million yuan will be used for the industrial Technology Research Institute project.

According to the prospectus, the revenue of BZBD in 2020, 2021 and 2022 will be 812 million yuan, 908 million yuan and 946 million yuan respectively; Net profit was 134 million yuan, 309 million yuan and 323 million yuan, respectively; Net profit after deduction was 267 million yuan, 304 million yuan and 320 million yuan, respectively. Revenue for the first quarter of 2023 was 225 million yuan, down 7.9% year-on-year; Net profit was 78.424 million yuan, down 15.65% year-on-year; Non-net profit was 77.05 million yuan, down 15% year-on-year.

Jiangsu BZBD was founded in 2006, in 2006 in Jiangsu Rugao Port industrial Park investment in a new production base, covering an area of 195,000 square meters, with modern production workshop and facilities. The company is mainly engaged in the production and sales of pharmaceutical raw materials, veterinary raw materials and fine chemicals. The company is mainly committed to providing customized production services for global plant protection, new materials and pharmaceutical companies, and engaged in the production and sales of some animal protection and pharmaceutical independent products.

In recent years, with the accumulation in the field of plant protection and new materials, BZBD has expanded new customers and new fields, established business cooperation or carried out development activities with BASF and many other enterprises, and provided customers with synthetic process route development and industrialization services for innovative drugs and other products.